MW Two software companies are going public. The IPO market is getting up off the mat.
By Steve Gelsi
Joint- and muscle-pain specialist Hinge Health raises $437 million, while marketing software maker MNTN draws in $187 million
Initial public offerings from Hinge Health Inc. and MNTN Inc. both priced at the top of their estimated ranges in a bullish sign for the two deals, as the market for initial public offerings continues to gear up after an absence of deals in recent weeks.
Hinge Health $(HNGE)$, which makes a device that eases muscle and joint pain as well as software to treat musculoskeletal issues, raised $437 million.
The company priced 13.67 million shares at $32 a share, the top of the estimated price range of $28 to $32 a share, with lead underwriters Morgan Stanley, Barclays and BofA Securities.
MNTN Inc. $(MNTN.UK)$, which makes marketing software aimed at streaming services such as Netflix Inc. $(NFLX)$ and Amazon.com Inc. $(AMZN)$, drew in $187 million by offering 11.7 million shares at $16 a share.
The Austin, Texas, company priced its IPO at the top of its $14 to $16 range with lead underwriters Morgan Stanley, Citigroup and Evercore ISI.
The two IPOs come just a few days after stock and crypto-trading company eToro Group Ltd. (ETOR) raised $620 million at an IPO price of $52 a share for trading on May 15. The stock closed at $66.12 on Wednesday.
With the strong performance from eToro, Hinge Health and MNTN are debuting on more solid ground despite continued volatility in the stock market.
Also read: Newly issued eToro shares jump in Nasdaq debut. It's a bullish sign for IPOs.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
May 22, 2025 09:01 ET (13:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。